oral semaglutide news Novo's Wegovy: Dead-Cat Bounce or True Inflection? Dr Reddy's Laboratories launches semaglutide

Clinical evidence now supports their use in non-obese individuals with metabolic conditions, with studies showing that semaglutide reduces cardiovascular events by 26% in patients with established heart disease

Lower-dose protocols may allow patients not seeking significant weight loss to explore the broad range of health benefits of GLP-1s while aiming to reduce side effects, preserve muscle, and keep treatment aligned with their long-term health goals

All animals create taurine naturally in their own bodies, including mammals, fish, shellfish, and poultry, including eggs

SARS-CoV-2 virus NSP14 Impairs NRF2/HMOX1 activation by targeting Sirtuin 1